Long‐Term Clinical‐Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy

Background The limited ability of enzyme replacement therapy (ERT) in removing globotriaosylceramide from cardiomyocytes is recognized for advanced Fabry disease cardiomyopathy (FDCM). Prehypertrophic FDCM is believed to be cured or stabilized by ERT. However, no pathologic confirmation is available...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Andrea Frustaci, Romina Verardo, Nicola Galea, Maria Alfarano, Michele Magnocavallo, Livia Marchitelli, Luigi Sansone, Manuel Belli, Mario Cristina, Emanuela Frustaci, Matteo Antonio Russo, Cristina Chimenti
Format:	Artigo
Sprog:	Inglês
Udgivet:	Wiley 2024-04-01
Serier:	Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Fag:	enzyme replacement therapy Fabry disease cardiomyopathy globotrioasylceramide mannose‐6‐phosphate receptors
Online adgang:	https://www.ahajournals.org/doi/10.1161/JAHA.123.032734
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!